Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024.
| Business Activity | PASS |
| Debt Ratio (5,339.25%) | FAIL |
| Cash Ratio (1,955.27%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2023-05-09 | -0.11 | -0.12 | -9.1% |
| 2023-03-28 | -0.12 | -0.11 | +8.3% |
| 2022-11-14 | -0.13 | -0.12 | +11.1% |
| 2022-08-09 | -0.14 | -0.13 | +10.3% |
| 2022-05-03 | -0.14 | -0.14 | -1.9% |
| 2022-03-29 | -0.14 | -0.13 | +3.9% |
| 2021-11-02 | -0.14 | -0.12 | +13.4% |
| 2021-07-27 | -0.14 | -0.13 | +4.7% |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Motiv8 Investments LLC | 200.0 | — | — |
$30.7M
-0.00
8.795
$2.6M
$48.5M
0.31
0.0%
30
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| IIPR | 0.334 |
| MANAZEL.KW | 0.256 |
| NP | 0.243 |
| KBNT | 0.237 |
| ACICO.KW | 0.237 |
| Ticker | Correlation |
|---|---|
| AVO | -0.255 |
| BB | -0.220 |
| TAALEEM.AE | -0.215 |
| HESM | -0.202 |
| SENEB | -0.200 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.